Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Isavuconazonium Sulfate

FDA-approved product (capsule, oral), marketed as Cresemba.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Isavuconazonium Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Mucormycosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC05

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Isavuconazonium Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Isavuconazonium Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug Interaction Study of Isavuconazole and Cyclosporine

    NCT01494597 · start 2011-11

    Registered record
    Registry ID
    NCT01494597
    Conditions
    Healthy
    Interventions
    isavuconazole; cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11
    Completion
    2011-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionisavuconazole; cyclosporine
    PhasePhase 1
    Registry statusCompleted

  • Drug Interaction Study of Isavuconazole and Midazolam

    NCT01406171 · start 2011-05

    Registered record
    Registry ID
    NCT01406171
    Conditions
    Pharmacokinetics of Isavuconazole; Pharmacokinetics of Midazolam; Healthy Volunteers
    Interventions
    Isavuconazole; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2011-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics of Isavuconazole; Pharmacokinetics of Midazolam; Healthy Volunteers
    InterventionIsavuconazole; Midazolam
    PhasePhase 1
    Registry statusCompleted

  • Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

    NCT00634049 · start 2008-04-22

    Registered record
    Registry ID
    NCT00634049
    Conditions
    Aspergillosis; Invasive Fungal Infections
    Interventions
    isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-04-22
    Completion
    2016-05-05
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis; Invasive Fungal Infections
    Interventionisavuconazole
    PhasePhase 3
    Registry statusCompleted

  • Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

    NCT00413218 · start 2007-03-08

    Registered record
    Registry ID
    NCT00413218
    Conditions
    Candidiasis, Invasive; Candidemia; Mycoses
    Interventions
    Isavuconazole; Caspofungin; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03-08
    Completion
    2015-03-03
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Invasive; Candidemia; Mycoses
    InterventionIsavuconazole; Caspofungin; Voriconazole
    PhasePhase 3
    Registry statusCompleted

  • Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy

    NCT00413439 · start 2006-05

    Registered record
    Registry ID
    NCT00413439
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2007-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionIsavuconazole
    PhasePhase 2 / Phase 3
    Registry statusCompleted